As reported in the NEJM the treatment led to complete remission in 44 of 53 patients (83%), and the entire cohort had a median survival exceeding 1 year. Patients with low disease burden had even longer prolonged median survival (20.1 months).

https://www.medpagetoday.com/hematologyoncology/leukemia/70917?xid=nl_mpt_DHE_2018-02-03&eun=g617309d0r&pos=4&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-02-03&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days